載入...
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
SRC is a tyrosine kinase that plays a role in oncogenic, invasive and bone-metastatic processes. It has therefore been prioritized as a candidate therapeutic target in patients with solid tumors. Several SRC inhibitors are now in development, of which dasatinib has been most explored. Preclinical st...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2010
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3940067/ https://ncbi.nlm.nih.gov/pubmed/20226597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2010.02.015 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|